PTAB Throws Out Janssen Patent for Prostate Cancer Drug

The PTO’s Patent Trial and Appeal Board ruled against a Janssen patent for its prostate cancer drug Zytiga, in another setback for the company in it its efforts to keep biosimilars and generics for its drugs off the market.
Source: Drug Industry Daily